Quris-AI, a leading Bio-AI innovator disrupting the drug development process using advanced artificial intelligence models, has acquired Nortis to improve its platform’s ability to predict drug safety and efficacy in humans.
The acquisition of the Brazil-based microphysiology systems (MPS) technology pioneer allows Quris-Ai to integrate Nortis’ Kidney-on-Chip technology into its Bio-AI platform, enhancing the company’s capability in helping pharmaceutical companies develop safe and effective medicines.
Enhancing Drug Safe and Efficacy Using Cutting-edge Technology
Quris-AI’s acquisition of Nortis goes beyond the company’s operational efficiency to the overall safety of drugs for humans.
Approved by the National Center for Advancing Translational Sciences (NCATS), Nortis’s Kidney-on-Chip models integration into Quris-AI’s platform marks a significant milestone in advancing in-vitro drug testing and the development of personalized medicine.
Quris-AI’s platform leverages the power of artificial intelligence and machine learning to simulate clinical trials, predicting the efficacy and safety of the drugs in the human body.
This helps to reduce the reliance on animal-based drug testing, accelerating the process of identifying promising candidates for clinical trials.
With this approach, Quris-AI aims to help pharmaceutical companies significantly reduce the time taken to develop new effective drugs for various illnesses.
By predicting drug safety and efficacy, the platform aims to transform drug discovery, improving patient outcomes.
